![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercepharma.com/pharma/roche-shows-durability-eye-disease-treatments-susvimo-and-vabysmo
https://www.fiercebiotech.com/biotech/genentech-sinks-shp2-pact-leaving-relay-race-thinning-field
https://www.globenewswire.com/news-release/2024/07/17/2914761/0/en/Roche-s-Vabysmo-showed-extended-durability-continued-efficacy-and-a-consistent-safety-profile-in-long-term-diabetic-macular-edema-DME-study.html
https://www.pharmaceutical-technology.com/news/nhs-rolls-out-more-convenient-ocrevus-injection-for-multiple-sclerosis/
https://www.indianpharmapost.com/news/roche-receives-ce-mark-for-its-ai-enabled-continuous-glucose-monitoring-solution-15867
https://www.fiercepharma.com/marketing/roche-rises-and-sanofi-slips-ranking-big-pharmas-online-activities
https://www.fiercebiotech.com/medtech/roche-nets-european-approval-ai-powered-cgm-type-1-type-2-diabetes
https://www.globenewswire.com/news-release/2024/07/09/2910036/0/en/Roche-receives-CE-Mark-for-its-AI-enabled-continuous-glucose-monitoring-solution-offering-critical-predictions-to-people-living-with-diabetes.html